Integrated Filing — IndAS

General information about company
Scrip Code	506943
NSE Symbol	JBCHEPHARM
MSEI Symbol	NOTLISTED
ISIN	INE572A01036
Name of company	JB Chemicals & Pharmaceuticals Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	14-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-Apr-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	14-May-2025   17:30:00
End date and time of board meeting	14-May-2025   18:31:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2022-03-22
Indicate Company website link for updated RPT policy of the Company	https://jbpharma.com/wp-content/uploads/2024/04/4.-RPT-policy_compressed.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
Format for disclosing outstanding default on loans and debt securities is not applicable for the quarter ended March 31, 2025 as there was no default.

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	9013400000	37229200000
	Other income	135300000	347400000
	Total income	9148700000	37576600000
2	Expenses
(a)	Cost of materials consumed	1889700000	8200400000
(b)	Purchases of stock-in-trade	1041300000	4166500000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	103500000	155300000
(d)	Employee benefit expense	1661200000	6467900000
(e)	Finance costs	9300000	91200000
(f)	Depreciation, depletion and amortisation expense	444100000	1664500000
(f)	Other Expenses
1	Other expenses	2007900000	8059700000
	Total other expenses	2007900000	8059700000
	Total expenses	7157000000	28805500000
3	Total profit before exceptional items and tax	1991700000	8771100000
4	Exceptional items	0	0
5	Total profit before tax	1991700000	8771100000
6	Tax expense
7	Current tax	435900000	1916900000
8	Deferred tax	57800000	328800000
9	Total tax expenses	493700000	2245700000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	1498000000	6525400000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	1498000000	6525400000
17	Other comprehensive income net of taxes	25900000	-34700000
18	Total Comprehensive Income for the period	1523900000	6490700000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	155700000	155700000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		33616300000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	9.63	42
	Diluted earnings (loss) per share from continuing operations	9.44	41.16
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	9.63	42
	Diluted earnings (loss) per share from continuing and discontinued operations	9.44	41.16
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	6066000000
	Capital work-in-progress	459600000
	Investment property
	Goodwill	43200000
	Other intangible assets	12723700000
	Intangible assets under development	157300000
	Biological assets other than bearer plants
	Investments accounted for using equity method
	Non-current financial assets
	Non-current investments	1708600000
	Trade receivables, non-current
	Loans, non-current	3500000
	Other non-current financial assets	2558100000
	Total non-current financial assets	4270200000
	Deferred tax assets (net)
	Other non-current assets	155200000
	Total non-current assets	23875200000
2	Current assets
	Inventories	4716400000
	Current financial asset
	Current investments	3171100000
	Trade receivables, current	7680900000
	Cash and cash equivalents	762100000
	Bank balance other than cash and cash equivalents	143600000
	Loans, current	5500000
	Other current financial assets	185600000
	Total current financial assets	11948800000
	Current tax assets (net)	117200000
	Other current assets	1121400000
	Total current assets	17903800000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	41779000000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	155700000
	Other equity	33616300000
	Total equity attributable to owners of parent	33772000000
	Non controlling interest
	Total equity	33772000000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
	Total Trade payable
	Other non-current financial liabilities	59200000
	Total non-current financial liabilities	59200000
	Provisions, non-current	221900000
	Deferred tax liabilities (net)	1862500000
	Deferred government grants, Non-current
	Other non-current liabilities	19000000
	Total non-current liabilities	2162600000
	Current liabilities
	Current financial liabilities
	Borrowings, current	0
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	370000000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	3475900000
	Total Trade payable	3845900000
	Other current financial liabilities	1117300000
	Total current financial liabilities	4963200000
	Other current liabilities	214800000
	Provisions, current	591800000
	Current tax liabilities (Net)	74600000
	Deferred government grants, Current
	Total current liabilities	5844400000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	8007000000
	Total equity and liabilites	41779000000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Unaudited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Re-measurement of defined benefit plan	-1300000	-59200000
	Total Amount of items that will not be reclassified to profit and loss	-1300000	-59200000
2	Income tax relating to items that will not be reclassified to profit or loss	-300000	-14900000
3	Amount of items that will be reclassified to profit and loss
1	Cash flow hedge reserve	35900000	12800000
	Total Amount of items that will be reclassified to profit and loss	35900000	12800000
4	Income tax relating to items that will be reclassified to profit or loss	9000000	3200000
5	Total Other comprehensive income	25900000	-34700000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Unaudited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			8771100000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			91200000
	Adjustments for decrease (increase) in inventories			-104400000
	Adjustments for decrease (increase) in trade receivables, current			-661400000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-268300000
	Adjustments for decrease (increase) in other non-current assets			-1400000
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			822800000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			0
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			1664500000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			-33900000
	Adjustments for dividend income			100000
	Adjustments for interest income			21300000
	Adjustments for share-based payments			534800000
	Adjustments for fair value losses (gains)			-53800000
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			29000000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			1997700000
	Net cash flows from (used in) operations			10768800000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			1928400000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			8840400000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			7500000
	Purchase of property, plant and equipment			960800000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			147000000
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			100000
	Interest received			13400000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-1812500000
	Net cash flows from (used in) investing activities	-2899300000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			240000000
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			3423800000
	Payments of lease liabilities			116500000
	Dividends paid			2370400000
	Interest paid			71900000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-5742600000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			198500000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			-100000
	Net increase (decrease) in cash and cash equivalents			198400000
	Cash and cash equivalents cash flow statement at beginning of period			563700000
	Cash and cash equivalents cash flow statement at end of period			762100000